Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: A comparison of three drugs

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 253-265

  Nitta, Y ^a   Yamamoto, R ^a   Yamaguchi, Y ^a   Katsuda, S ^a   Kaku, B ^a   Taguchi, T ^a   Takabatake, S ^b   Nakahama, K ^b   Yamagishi, M ^b  

^a TOYAMA RED CROSS HOSPITAL   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Amlodipine; Benidipine; Calcium channel blocker; Cardiovascular disease; Chronic kidney disease; Coronary artery disease; Hypertension; Nifedipine; Prognosis

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENIDIPINE; NIFEDIPINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEART DEATH; HEART INFARCTION; HEART RATE; HOSPITAL DISCHARGE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; UNSTABLE ANGINA PECTORIS;

EID: 77749277414     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800130     Document Type: Article

References (24)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
2. Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031.
3. Nissen SE, Tuzcu EM, Libby P, et al for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
4. Walter MF, Jacob RF, Bjork RE, et al for the PREVENT Investigators: Circulating lipid hydroperoxides predict cardiovascular events in patients with stable coronary artery disease: the PREVENT study. J Am Coll Cardiol 2008; 51: 1196-1202.
5. Yui Y, Shinoda E, Kodama K, et al for the Japan Multicenter Investigation for Cardiovascular Diseases B (JMIC-B) Study Group: Nifedipine retard prevents hospitalization for angina pectoris better than angiotensin-converting enzyme inhibitors in hypertensive Japanese patients with previous myocardial infarction (JMIC-B substudy). J Hypertens 2007; 25: 2019-2026.
6. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al for the INVEST Investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
7. Maseri A, Beltrame JF, Shimokawa H: Role of coronary vasoconstriction in ischemic heart disease and search for novel therapeutic targets. Circ J 2009; 73: 394-403.
8. Shimokawa H, Nagasawa K, Irie T, et al: Clinical characteristics and long-term prognosis of patients with variant angina. A comparative study between Western and Japanese populations. Int J Cardiol 1988; 18: 331-349.
9. Yamagishi M, Ito K, Tsutsui H, et al: Lesion severity and hypercholesterolemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J 2003; 67: 1029-1035.
10. Ito A, Fukumoto Y, Shimokawa H: Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 2004; 44: 480-485.
11. Io K, Minatoguchi S, Nishigaki K, et al: Effects of benidipine and some other calcium channel blockers on the prognosis of patients with vasospastic angina. Cohort study with evaluation of the ergonovine coronary spasm induction test. Arzneimittelforschung 2007; 57: 573-581.
12. Fukumoto Y, Yasuda S, Ito A, et al: Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlodipine. J Cardiovasc Pharmacol 2008; 51: 253-257.
13. Austen WG, Edwards JE, Frye RL, et al: A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation 1975; 51(4 suppl): 5-40.
14. Ogihara T, Kikuchi K, Matsuoka H, et al for the Japanese Society of Hypertension (JSH) Committee: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
15. Matsuo S, Imai E, Horio M, et al: Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
16. Ninomiya T, Kiyohara Y, Kubo M, et al: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68: 228-236.
17. Taniwa T, Miyataka M, Kimura A, et al: Calcium antagonists for secondary prevention of myocardial infarction: is there a need to shift from short-acting to long-acting types? Circ J 2005; 69: 1308-1314.
18. Alderman MH, Cohen H, Roqué R, et al: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-598.
19. Karasawa A, Kubo K: Calcium antagonistic effects and the in vitro duration of actions of KW-3049, a new 1,4-dihydropyridine derivative, in isolated canine coronary arteries. Jpn J Pharmacol 1988; 47: 35-44.
20. Shimada S, Nakajima Y, Yamamoto K, et al: Comparative pharmacodynamics of eight calcium channel blocking agents in Japanese essential hypertensive patients. Biol Pharm Bull 1996; 19: 430-437.
21. Karasawa A, Nomura H, Nito M, et al: Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats. Nippon Yakurigaku Zasshi 1999; 113: 317-326 [in Japanese].
22. Akizuki O, Inayoshi A, Kitayama T, et al: Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584: 424-434.
23. Matsubara M, Yao K, Hasegawa K: Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharmacol Res 2006; 53: 35-43.
24. Yao K, Ina Y, Nagashima K, et al: Antioxidant effects of calcium antagonists in rat brain homogenates. Biol Pharm Bull 2000; 23: 766-769.